These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14534308)

  • 21. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis.
    Baron JH; Moiseeva EP; de Bono DP; Abrams KR; Gershlick AH
    Cardiovasc Res; 2000 Dec; 48(3):464-72. PubMed ID: 11090842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
    Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
    Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.
    Ndoko S; Poujol C; Combrié R; Nurden A; Nurden P
    Thromb Haemost; 2002 Feb; 87(2):317-22. PubMed ID: 11858493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-selectin expression on platelets determines size and stability of platelet aggregates.
    Merten M; Thiagarajan P
    Circulation; 2000 Oct; 102(16):1931-6. PubMed ID: 11034941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH; Sassoli PM; Jordan RE; Nakada MT
    Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GpIIb/IIIa is the main receptor for initial platelet adhesion to glass and titanium surfaces in contact with whole blood.
    Broberg M; Eriksson C; Nygren H
    J Lab Clin Med; 2002 Mar; 139(3):163-72. PubMed ID: 11944027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet integrin alpha IIb beta 3 (GPIIb-IIIa) is not implicated in the binding of LDL to intact resting platelets.
    Pedreño J; Fernández R; Cullaré C; Barceló A; Elorza MA; de Castellarnau C
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):156-63. PubMed ID: 9012651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
    Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV
    Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
    Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
    Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of platelet GPIIB-IIIA (Integrin alphaII(b)beta(3)) in flowing human blood leads to passivation of prothrombotic surfaces.
    Riederer MA; Ginsberg MH; Steiner B
    Thromb Haemost; 2002 Nov; 88(5):858-64. PubMed ID: 12428106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
    Barre DE
    Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty.
    Wu CH; Chen YC; Hsiao G; Lin CH; Liu CM; Sheu JR
    Thromb Res; 2001 Feb; 101(3):127-38. PubMed ID: 11228336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
    Tsao PW; Forsythe MS; Mousa SA
    Thromb Res; 1997 Oct; 88(2):137-46. PubMed ID: 9361367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The involvement of adhesion molecules and lipid mediators in the adhesion of human platelets to eosinophils.
    Jawień J; Lomnicka M; Korbut R; Chłopicki S
    J Physiol Pharmacol; 2005 Dec; 56(4):637-48. PubMed ID: 16391420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists.
    Gomes N; Vassy J; Lebos C; Arbeille B; Legrand C; Fauvel-Lafeve F
    Clin Exp Metastasis; 2004; 21(6):553-61. PubMed ID: 15679053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA; Khurana S; Forsythe MS
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.